Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) GF Score: 9/100 (As of Aug. 08, 2026) — 10% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02591 Guangzhou Innogen Pharmaceutical Group Co Ltd HKSE:02591
9 GF Score
Price HK$7.60
! 2 Warning Signs
View Full Analysis

What is Guangzhou Innogen Pharmaceutical Group Co GF Score?

Guangzhou Innogen Pharmaceutical Group Co HKSE:02591 +5.26% 9 GF Score is 9 as of Aug. 08, 2026, which is 10% below its 10-year median of 10.00. GuruFocus rates HKSE:02591 with a GF Score™ of 9/100. The stock has 2 warning signs investors should review.

Guangzhou Innogen Pharmaceutical Group Co has the GF Score of 9, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 6/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Guangzhou Innogen Pharmaceutical Group Co might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Guangzhou Innogen Pharmaceutical Group Co  (HKSE:02591) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Guangzhou Innogen Pharmaceutical Group Co GF Score Related Terms

HKSE:02591 vs VRTX, REGN, RVMD: GF Score Comparison

For the Biotechnology subindustry, Guangzhou Innogen Pharmaceutical Group Co's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Guangzhou Innogen Pharmaceutical Group Co GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Guangzhou Innogen Pharmaceutical Group Co's GF Score distribution charts can be found below:

* The bar in red indicates where Guangzhou Innogen Pharmaceutical Group Co's GF Score falls into.


HKSE:02591
9GF Score
Guangzhou Innogen Pharmaceutical Group Co Ltd HKSE:02591
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 9 mean?
Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) has a GF Score of 9 as of Aug. 08, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Guangzhou Innogen Pharmaceutical Group Co and its competitors. This is 10% below median its historical median of 10.00. Over the past decade, Guangzhou Innogen Pharmaceutical Group Co's GF Score has ranged from 7.00 to 14.00.
Is Guangzhou Innogen Pharmaceutical Group Co's GF Score too high?
Guangzhou Innogen Pharmaceutical Group Co's current GF Score of 9 is 10% below median its 10-year median of 10.00. Over the past 10 years, this metric has ranged from a low of 7.00 to a high of 14.00. Overall, Guangzhou Innogen Pharmaceutical Group Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Innogen Pharmaceutical Group Co's GF Score compare to VRTX and REGN?
Guangzhou Innogen Pharmaceutical Group Co's GF Score of 9 can be compared against companies in the Biotechnology industry. Historically, Guangzhou Innogen Pharmaceutical Group Co's own GF Score has ranged from 7.00 to 14.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Guangzhou Innogen Pharmaceutical Group Co and its competitors. Guangzhou Innogen Pharmaceutical Group Co's current GF Score is 9, which is 10% below median its own 10-year median of 10.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Innogen Pharmaceutical Group Co stock overvalued right now?
Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) has a current GF Score of 9. The current GF Score is 9, which is 10% below median its 10-year median of 10.00. Guangzhou Innogen Pharmaceutical Group Co's overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591), the current GF Score is 9 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Guangzhou Innogen Pharmaceutical Group Co Business Description

Address No. 2 Tengfei Second Street, Room 409, Building H Self-numbered Creative Building, China-Singapore Guangzhou Knowledge City, Huangpu District, Guangdong Province, Guangzhou, CHN
Guangzhou Innogen Pharmaceutical Group Co Ltd is a company in Asia to commercialize, a humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It has commercialized Efsubaglutide Alfa (brand name: Diabegone), its Core Product, for the treatment of type 2 diabetes (T2D) in China. Its core business model is to discover, develop and commercialize therapies for diabetes and other metabolic diseases. The company has built a pipeline of drug candidates namely YN014, YN401, YN209, YN202,YN203 targeting diabetes and other metabolic diseases.
9GF Score

Get the complete analysis for HKSE:02591

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$7.60
Price